用于优化急性心肌梗死溶栓治疗的糖蛋白IIb/IIIa受体阻滞剂

[GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].

作者信息

Nordt T K, Peter K, Bode C

机构信息

Abteilung Innere Medizin III (Schwerpunkt Kardiologie und Angiologie), Universitätsklinikum Freiburg.

出版信息

Herz. 2001 Apr;26 Suppl 1:42-5. doi: 10.1007/pl00014031.

DOI:10.1007/pl00014031

PMID:11349626

Abstract

Thrombolytic therapy is an established strategy for the treatment of acute myocardial infarction. GPIIB/IIIA BLOCKERS + MODERN THROMBOLYTIC AGENTS: At present, the most attractive development for optimizing thrombolytic therapy includes the use of GPIIb/IIIa blockers in combination with modern thrombolytic agents such as alteplase and reteplase. The review summarizes the available results of clinical studies using standard doses of thrombolytic agents (TAMI 8, IMPACT-AMI, and PARADIGM) or reduced dosages of thrombolytic agents (TIMI 14 and SPEED) for combination therapy. The review also focuses on the implications of the combination therapy for coronary angioplasty immediately following coronary thrombolysis.

摘要

溶栓治疗是治疗急性心肌梗死的既定策略。糖蛋白IIb/IIIa受体阻滞剂+现代溶栓剂：目前，优化溶栓治疗最具吸引力的进展包括将糖蛋白IIb/IIIa受体阻滞剂与阿替普酶和瑞替普酶等现代溶栓剂联合使用。该综述总结了使用标准剂量溶栓剂（TAMI 8、IMPACT-AMI和PARADIGM）或降低剂量溶栓剂（TIMI 14和SPEED）进行联合治疗的临床研究现有结果。该综述还重点关注联合治疗对冠状动脉溶栓后立即进行冠状动脉血管成形术的影响。